Page 2 - Arthur Roach News Today

NRG Therapeutics announces multi-million Innovate UK Award to develop treatments for Parkinson’s and motor neurone disease - News - PharmaTimes

UK neuroscience company NRG Therapeutics Ltd has received an award to fund preclinical development of its novel small molecule disease-modifying medicines for the treatment of Parkinson's disease, motor neuron disease (MND) and other chronic neurodegenerative disorders.

NRG Therapeutics Ltd (“NRG” or “company”), an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has received a highly competitive Biomedical Catalyst (BMC) award to fund pre-clinical development of its novel small molecule disease-modifying medicines for the treatment of Parkinson's disease, motor neuron disease (MND) and other debilitating chronic neurodegenerative disorders.

/PRNewswire/ -- NRG Therapeutics Ltd ("NRG" or "company"), an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that...

In recognition of World Parkinson's Day, we speak to Dr. Arthur Roach, Director of Research at Parkinson’s UK, about the current Parkinson's landscape.

Echoes is the opinion section of TheBostonPilot.com. The Boston Pilot is a daily news Catholic newspaper based in Boston, Massachusetts, covering news and opinion about the Catholic Church and Catholic life. We carry daily news from Boston, New England, US, the Vatican, Europe, Africa, Asia, and Central and Latin America. The Boston Pilot is part of the Pilot Media Group, Americas oldest Catholic newspaper and the official newspaper of the Archdiocese of Boston.

Apr 26 2021 Read 13 Times Researchers at the University of Sheffield have been awarded £1.2 million from Parkinson’s UK to continue with development of a drug that protects dopamine-producing brain cells in efforts to halt the degenerative disease. Dopamine is a chemical which allows messages to be sent to the parts of the brain that help to coordinate movement. To do this effectively, the dopamine-producing brain cells need to be constantly active and they rely on mitochondria to function p...

Parkinson’s UK, University of Sheffield to develop new Parkinson’s drug Parkinsons UK, the largest charitable funder of Parkinsons research in Europe, is investing up to £1.2 million into a pioneering one-year project in partnership with the University of Sheffield. The project aims to refine a molecule that could be developed into a drug to protect dopamine-producing brain cells and slow down the progression of Parkinsons. The funding boost comes via the charitys Parkinsons Virtual Biotec...

Parkinson’s UK creates Vivifi Biotech to research ‘promising’ experimental treatment 24th February 2021 Charity organisation Parkinson’s UK has announced it is creating a dedicated company to drive forward research into an experimental treatment for Parkinson’s disease. The company, Vivifi Biotech, has been created through the Parkinson’s Virtual Biotech – the drug development arm of Parkinson’s UK. It will seek to further the development of Glial Cell-Line Derived Neurotrophic ...